Traditional Chinese Medicine Formula Treats Post-Stroke Depression via Gut Microbiome
Xiaoyaosan herbal formula improves depression after stroke by restoring healthy gut bacteria and reducing brain inflammation in mice.
Summary
Researchers found that Xiaoyaosan (XYS), a traditional Chinese medicine formula, effectively treats depression-like behaviors in mice following stroke. The treatment works by restoring healthy gut bacteria composition and reducing inflammation in both the intestines and brain. XYS increased beneficial bacteria like Faecalibaculum while decreasing harmful ones like Streptococcus. The formula also regulated inflammatory pathways and improved intestinal barrier function. Remarkably, transplanting gut bacteria from XYS-treated mice into depressed mice reproduced the therapeutic benefits, confirming the gut-brain connection's role in post-stroke depression recovery.
Detailed Summary
Post-stroke depression affects up to 30% of stroke survivors and significantly impacts recovery outcomes. This study reveals how traditional Chinese medicine may offer a novel therapeutic approach through the gut-brain axis.
Researchers tested Xiaoyaosan (XYS), a centuries-old herbal formula, in mice with post-stroke depression. They used comprehensive methods including behavioral testing, gut microbiome sequencing, metabolomics, and fecal transplantation experiments to understand the mechanism.
XYS treatment dramatically improved depression-like behaviors and repaired damaged intestinal tissue. The formula restored healthy gut bacteria balance by increasing beneficial species like Faecalibaculum and Allobaculum while reducing harmful bacteria including Streptococcus and Staphylococcus. XYS also regulated key metabolites and suppressed inflammatory pathways involving P2X7R/NLRP3 inflammasomes in both gut and brain tissue.
Most compelling was the fecal transplantation experiment: transferring gut bacteria from XYS-treated mice to depressed mice reproduced the antidepressant effects, proving the microbiome's causal role. This suggests post-stroke depression involves gut dysbiosis that can be therapeutically targeted.
These findings could revolutionize post-stroke care by identifying the gut microbiome as a treatment target. However, translation from mice to humans requires clinical validation, and the complex herbal formula's active components need identification for standardized treatment protocols.
Key Findings
- XYS treatment restored healthy gut bacteria and reduced harmful species in post-stroke depression
- Fecal transplantation from treated mice reproduced antidepressant effects in recipient mice
- Treatment suppressed P2X7R/NLRP3 inflammatory pathways in both gut and brain tissue
- XYS regulated key intestinal metabolites including methylparaben and valproic acid
- Gut microbiome changes directly contributed to depression-like behaviors after stroke
Methodology
Mouse study using post-stroke depression model with behavioral testing, 16S rRNA sequencing for microbiome analysis, metabolomics, and fecal microbiota transplantation experiments. Multiple assessment methods including histology, protein expression analysis, and inflammatory marker measurement.
Study Limitations
Animal study requiring human clinical validation. Complex herbal formula makes it difficult to identify specific active compounds. Long-term safety and optimal dosing protocols need establishment before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.